Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers [Yahoo! Finance]
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.